ReviewCancer medicine2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
Review in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma.Future oncology (London, England) · 2026Pooled it
- Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.British journal of haematology · 2026Observational
- Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.Cancers · 2026Review
- Classical Hodgkin Lymphoma Today.Mediterranean journal of hematology and infectious diseases · 2026Review
- Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.Cancers · 2025Article
- ΔSUVmax adds prognostic value to early response assessment during the first-line treatment of classical hodgkin lymphoma: a retrospective cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials.Frontiers in oncology · 2025Article
- Impact of secondary hematologic malignancies on prognosis of Hodgkin's lymphoma survivors.Frontiers in oncology · 2025Article
- Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study.HemaSphere · 2024Article
- Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review.Annals of hematology · 2024Review
- Treatment Strategies in Advanced-Stage Hodgkin Lymphoma.Cancers · 2024Review
- Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP).Medicina (Kaunas, Lithuania) · 2024Article
- Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study.The Indian journal of medical research · 2024Article
- Bone damage and health-related quality of life in Hodgkin lymphoma survivors: closing the gaps.Frontiers in oncology · 2024Review
- The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective.JCO oncology practice · 2023Observational
- Advances in the treatment of Hodgkin lymphoma: Current and future approaches.Frontiers in oncology · 2023Review
- [The guidelines for diagnosis and treatment of Hodgkin lymphoma in China (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 17 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe explored the potential overall survival (OS) benefit of bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (BEACOPP) over doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) in a pooled analysis of four randomized trials. PATIENTS AND
methodsPrimary objective was to evaluate the OS impact of BEACOPP using individual patient data. Secondary objectives were progression-free survival (PFS), secondary cancers, and use of autologous stem cell transplantation (ASCT).
resultsAbout 1227 patients were included. The 7-year OS was 84.3% (95% CI 80.8-87.2) for ABVD vs 87.7% (95% CI 84.5-90.2) for BEACOPP. Two follow-up periods were identified based on survival curves and hazard ratio (HR) over time. For the first 18 months, there was no difference. For the second period of ≥18 months, ABVD patients had a higher death risk (HR
conclusionsThis analysis showed a slight improvement in OS for BEACOPP and confirmed a PFS benefit. Frontline use of BEACOPP instead of ABVD increased secondary leukemia incidence but halved the requirement for ASCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.